To include your compound in the COVID-19 Resource Center, submit it here.

Otsuka begins Phase III trials of brexpiprazole to treat manic episodes

In October, Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and partner H. Lundbeck A/S (CSE:LUN) began two identical Phase III trials of Rexulti brexpiprazole (OPC-34712)

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE